Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate
1. MLYS reported successful Phase 3 and Phase 2 trial results for lorundrostat. 2. Lorundrostat showed significant reductions in systolic blood pressure compared to placebo. 3. Trials demonstrated favorable safety and tolerability profiles for lorundrostat. 4. MLYS stock increased 65.70% following positive trial results. 5. FDA cleared lorundrostat for future trials in obstructive sleep apnea.